Half of All Children Will Be Autistic by 2025, Warns Senior Research Scientist at MIT | The Alliance for Natural Health USA


Why? Evidence points to glyphosate toxicity from the overuse of Monsanto’s Roundup herbicide on our food.

For over three decades, Stephanie Seneff, PhD, has researched biology and technology, over the years publishing over 170 scholarly peer-reviewed articles. In recent years she has concentrated on the relationship between nutrition and health, tackling such topics as Alzheimer’s, autism, and cardiovascular diseases, as well as the impact of nutritional deficiencies and environmental toxins on human health.

At a conference last Thursday, in a special panel discussion about GMOs, she took the audience by surprise when she declared, “At today’s rate, by 2025, one in two children will be autistic.”She noted that the side effects of autism closely mimic those of glyphosate toxicity, and presented data showing a remarkably consistent correlation between the use of Roundup on crops (and the creation of Roundup-ready GMO crop seeds) with rising rates of autism. Children with autism have biomarkers indicative of excessive glyphosate, including zinc and iron deficiency, low serum sulfate, seizures, and mitochondrial disorder.

A fellow panelist reported that after Dr. Seneff’s presentation, “All of the 70 or so people in attendance were squirming, likely because they now had serious misgivings about serving their kids, or themselves, anything with corn or soy, which are nearly all genetically modified and thus tainted with Roundup and its glyphosate.”

Dr. Seneff noted the ubiquity of glyphosate’s use. Because it is used on corn and soy, all soft drinks and candies sweetened with corn syrup and all chips and cereals that contain soy fillers have small amounts of glyphosate in them, as do our beef and poultry since cattle and chicken are fed GMO corn or soy. Wheat is often sprayed with Roundup just prior to being harvested, which means that all non-organic bread and wheat products would also be sources of glyphosate toxicity. The amount of glyphosate in each product may not be large, but the cumulative effect (especially with as much processed food as Americans eat) could be devastating. A recent study shows that pregnant women living near farms where pesticides are applied have a 60% increased risk of children having an autism spectrum disorder.

Other toxic substances may also be autism-inducing. You may recall our story on the CDC whistleblower who revealed the government’s deliberate concealment of the link between the MMR vaccine (for measles, mumps, and rubella) and a sharply increased risk of autism, particularly in African American boys. Other studies now show a link between children’s exposure to pesticides and autism. Children who live in homes with vinyl floors, which can emit phthalate chemicals, are more likely to have autism. Children whose mothers smoked were also twice as likely to have autism. Research now acknowledges that environmental contaminants such as PCBs, PBDEs, and mercury can alter brain neuron functioning even before a child is born.

This month, the USDA released a study finding that although there were detectable levels of pesticide residue in more than half of food tested by the agency, 99% of samples taken were found to be within levels the government deems safe, and 40% were found to have no detectable trace of pesticides at all. The USDA added, however, that due to “cost concerns,” it did not test for residues of glyphosate. Let’s repeat that: they never tested for the active ingredient in the most widely used herbicide in the world. “Cost concerns”? How absurd—unless they mean it will cost them too much in terms of the special relationship between the USDA and Monsanto. You may recall the revolving door between Monsanto and the federal government, with agency officials becoming high-paying executives—and vice versa! Money, power, prestige: it’s all there. Monsanto and the USDA love to scratch each others’ backs. Clearly this omission was purposeful.

In addition, as we have previously reported, the number of adverse reactions from vaccines can be correlated as well with autism, though Seneff says it doesn’t correlate quite as closely as with Roundup. The same correlations between applications of glyphosate and autism show up in deaths from senility.

Of course, autism is a complex problem with many potential causes. Dr. Seneff’s data, however, is particularly important considering how close the correlation is—and because it is coming from a scientist with impeccable credentials. Earlier this year, she spoke at the Autism One conference and presented many of the same facts; that presentation is available on YouTube.

Monsanto claims that Roundup is harmless to humans. Bacteria, fungi, algae, parasites, and plants use a seven-step metabolic route known as the shikimate pathway for the biosynthesis of aromatic amino acids; glyphosate inhibits this pathway, causing the plant to die, which is why it’s so effective as an herbicide. Monsanto says humans don’t have this shikimate pathway, so it’s perfectly safe.

Dr. Seneff points out, however, that our gut bacteria do have this pathway, and that’s crucial because these bacteria supply our body with crucial amino acids. Roundup thus kills beneficial gut bacteria, allowing pathogens to grow; interferes with the synthesis of amino acids including methionine, which leads to shortages in critical neurotransmitters and folate; chelates (removes) important minerals like iron, cobalt and manganese; and much more.

Even worse, she notes, additional chemicals in Roundup are untested because they’re classified as “inert,” yet according to a 2014 study in BioMed Research International, these chemicals are capable of amplifying the toxic effects of Roundup hundreds of times over.

Glyphosate is present in unusually high quantities in the breast milk of American mothers, at anywhere from 760 to 1,600 times the allowable limits in European drinking water. Urine testing shows Americans have ten times the glyphosate accumulation as Europeans.

“In my view, the situation is almost beyond repair,” Dr. Seneff said after her presentation. “We need to do something drastic.”

Scientists create artificial human sperm, eggs from stem cells.


Reuters / Yves Herman

Scientists from Cambridge University have created artificial human eggs and sperm for the first time, using human embryonic stem cells and skin cells.

While this process was previously achieved in rats, this is the first time it has been done with humans. The findings were published in the journal ‘Cell.’

However, the end result was not working sperm and eggs, but so-called germ cells that could potentially mature to become viable for fertility.

“Germ cells are ‘immortal’ in the sense that they provide an enduring link between all generations, carrying genetic information from one generation to the next,” Azim Surani, professor of physiology and reproduction at the University of Cambridge, said in a press release.

In biology, when an egg is fertilized by sperm, it divides into a group of cells called a blastocyst, which then develops into a fetus or the placenta.

Some cells become stem cells, which can then develop into any cell in the body. Some of these will become germ cells, and will then become sperm or eggs.

The scientists identified a gene known as SOX17, which decides which cells become sperm and egg cells. They then harvested these cells by culturing human embryonic stem cells for five days.

However, this doesn’t mean that men and women can donate any cells instead of sperm and eggs when they visit a fertility clinic – but the scientists hope the experiment will shed more light on the study of human genetics.

The research also gives scientists another way to examine how the environment impacts genes, such as how behavioral factors – like smoking and what we eat – can activate or deactivate genes.

The study of how genes are affected by environmental factors is known as epigenetics, and scientists hope it will give them a better understanding of cancer and other age-related illnesses.

Canadian scientists develop trap to lure blood-sucking bed bugs .


Bed bugs (AFP Photo)

Scientists from Simon Fraser University in Canada have invented an effective bait-and-trap against bed bugs that uses chemical attractants, or pheromones. In order to test the trap, a team member had to endure up to 180,000 bites from the nasty insects.

The bait, which the scientists say will be commercially available next year, turned out to be a real ordeal to develop.
Regine Gries, one of the biologists on the team, discovered the needed pheromones after acting as a host to thousands of bedbugs during her research.

“You can feed it on the blood of chickens or guinea pigs, but that’s not their preferred blood. To get the best results, and not jeopardize their chemical profiles, it was important to feed them human blood,” Gries told National Post.

 

Luckily, because Gries is immune to the bites, she only developed a slight rash – as opposed to the painful itching and swelling that most people experience.

The insects were largely wiped out after the Second World War, but have made a comeback, particularly in the US and Canada.

The hardy little bugs can go for months without feeding, meaning they can lie undetected in furniture and mattresses.

“The biggest challenge in dealing with bedbugs is to detect the infestation at an early stage. This trap will help landlords, tenants, and pest-control professionals determine whether premises have a bedbug problem, so that they can treat it quickly. It will also be useful for monitoring the treatment’s effectiveness,”said researcher Gerhard Gries in a news release on Monday.

 

When the research began eight years ago, the scientists isolated a pheromone mix that attracted bedbugs in lab conditions, but not in actual areas where bed bugs were living. After two years of research, Gries and SFU chemist Robert Britton discovered the crucial chemical histamine, which literally signals safe shelter to the blood-sucking bugs.

The team is now working with Victoria-based Contech Enterprises Inc. to develop the bed bug trap commercially.

16 Foods That Help You Sleep.


Many foods contain naturally occurring substances that bring on sleep; here are some of the best choices to help you settle down for a quality rest.

Read more: http://www.rd.com/slideshows/foods-that-help-you-sleep/#ixzz3NGloqwethttp://www.rd.com/slideshows/foods-that-help-you-sleep/?utm_content=buffercbd2a&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer

From the desk of Zedie.

Quick Brain Health Test For Stroke Risk.


What if we told you that trying to stand on one leg for 20 seconds (or more) could help you gauge the health of your brain? You might think we were a bit unbalanced ourselves. But that’s exactly what a new study published in the journal Stroke suggests.

Researchers at the Center for Genomic Medicine at Kyoto University in Japan asked about 1,400 people (average age 67) to stand with one leg raised and their eyes open for up to 60 seconds. Everyone tried this twice; best times were used for analysis. Then, using MRI, the researchers scanned everyone’s brain.

They found that those who struggled to balance for 20 seconds had cerebral small-vessel disease (SVD), even though they weren’t exhibiting any classic symptoms. SVD is related to stroke, dementia and even Parkinson’s. Among the balance-impaired, 15% had one micro-bleed brain lesion (30% had two) and 16% had one arterial brain blockage (35% had two.) In addition, those with the shortest balance times generally had the lowest mental performance scores.

How can standing on one leg provide insight into the brain’s health? “Balance is achieved and maintained by 3 main sensory circuits,” explains Jose Biller, MD, chair of neurology at Loyola Medicine in Maywood, IL. “Vision, proprioception [your sense of body position] and the vestibular system [inner ear, etc.].” If you were paying attention in high school anatomy, you’ll remember that the brain controls all these sensory circuits. So any loss of motor coordination, such as the inability to balance for any length of time, could suggest brain damage.

So take the balance test to see how you do. If you can’t break that 20-second threshold then, according to  Biller, you may be at increased risk for brain disease and cognitive decline. Consult with your physician.

Cannabis Oil Unveiled


Cannabis-Oil

Although I’ve been aware of the recent positive feedback of cannabis oil to various serious diseases, I was still skeptical to consider this as a viable solution for certain health disorders. After all, so many people these days are looking for the perfect miracle pill to solve their health issues!

Was this another panacea? Was this another way of buying into the one size fits all treatments that come into the bottle, without being necessary to make any dietary and life style changes? Well, in the end, it all depends on how we really make use of these extracts that Nature provided us and how clearly we see the “big picture” of true healing. So it was time to find out more! I interviewed one of my colleagues with extensive knowledge on the matter – Steven Sinay, a fellow Metabolic Typing® practitioner, as well as VP of Nutritional Science for Empower Genetics,and below is what he kindly shared with me regarding this interesting topic:

Raluca Schachter: What is cannabis oil more specifically and how does it work?

Steven Sinay: Cannabis Oil is a thick, sticky, resinous substance that is extracted from the cannabis plant (Cannabis sativa or Cannabis indica). Cannabis oil is a base product that is prepared by separating the resins from the cannabis flowers (buds) using a solvent extraction process. Cannabis oil contains several Cannabinoids including Tetrahydrocannabinol (THC), the psychoactive component, and Cannabidiol (CBD), the medicinal component of cannabis.

For legal purposes becoming more commonly used over Cannabis oil, is Hemp oil which is being grown in Europe to have higher levels of CBD and with no THC. In 2001, the DEA issued a rule banning all import and cultivation of industrial grade hemp. In 2003, the Hemp Industries Associationfiled an Urgent Motion for Stay in the Ninth Circuit Court of Appeals. In 2004, the Ninth Circuit Court sided with the Hemp Industries Association.

In the decision, Judge Betty Fletcher wrote, “[T]hey (DEA) cannot regulate naturally occurring THC not contained within or derived from marijuana-i.e., non-psychoactive hemp is not included in Schedule I. The DEA has no authority to regulate drugs that are not scheduled, and it has not followed procedures required to schedule a substance. The DEA’s definition of “THC” contravenes the unambiguously expressed intent of Congress in the Controlled Substances Act (CSA) and cannot be upheld.”

Judge Fletcher is essentially saying that the DEA cannot regulate hemp or the chemicals within it because hemp contains no THC, is not marijuana, and is therefore not covered under the controlled substances act; and the DEA cannot regulate substances that have not been scheduled. This is why you can purchase and sell CBD hemp oil.

Over the last 20 years Cannabis has been at the center of one of the most exciting and underreported developments in recent modern science. Research on marijuana’s effects led directly to the discovery of an unknown biochemical communication system in the human body, the Endocannabinoid System, which plays a crucial role in regulating our physiology, mood, and everyday experience.

The discovery of receptors in the brain that respond pharmacologically to Cannabis and the subsequent identification of endogenous cannabinoid compounds in our own bodies that bind to these receptors has significantly advanced our understanding of human biology, health, and disease.

It is an established scientific fact that cannabinoids and other components of cannabis can modulate many physiological systems in the human brain and body. Cannabinoids are chemical compounds that trigger cannabinoid and other receptors. More than 100 cannabinoids have been identified in the marijuana plant. Of these, THC and CBD have been studied most extensively. In addition to cannabinoids produced by the plant, there are endogenous cannabinoids (anandamide and 2AG) that occur naturally in the body, as well as synthetic cannabinoids created by pharmaceutical researchers.

Cannabinoids promote homeostasis at every level of biological life, from the sub-cellular, to the organism, and perhaps to the community and beyond. Here’s one example: autophagy, a process in which a cell sequesters part of its contents to be self-digested and recycled, is mediated by the cannabinoid system. While this process keeps normal cells alive, allowing them to maintain a balance between the synthesis, degradation, and subsequent recycling of cellular products, it has a deadly effect on malignant tumor cells, causing them to consume themselves in a programmed cellular suicide. The death of cancer cells, of course, promotes homeostasis and survival at the level of the entire organism.

Scientists associated with the International Cannabinoid Research Society (ICRS) have elucidated a number of molecular pathways whereby CBD exerts a therapeutic impact. A preclinical study by Dr. Sean McAllister and his colleagues at the California Pacific Medical Center in San Francisco reports on how CBD kills breast cancer by down regulating a gene called ID-1, which is implicated in several types of aggressive cancer. Silencing the ID-1 gene is thus is an excellent strategy for a cancer treatment.

Extensive preclinical research much of it sponsored by the U.S. Government (see U.S. Patent below) indicates that CBD has potent anti-tumoral, antioxidant, anti-spasmodic, anti-psychotic, anti-convulsive, and neuroprotective properties. CBD directly activates serotonin receptors, causing an anti-depressant effect, as well.

The United States Government holds U.S. Patent 6,630,507 (filed 1999) on Cannabinoids stating in their patent: “Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.”

Raluca Schachter: With what conditions has cannabis oil proved to be most successful?

Steven Sinay: According to many CBD Researchers the following are a list of conditions that the use of CBD has been shown to improve: Acne, ADD/ADHD, Addiction, AIDS, ALS, Alzheimer’s Disease, Anorexia, Antibiotic Resistance, Anxiety, Atherosclerosis, Arthritis, Asthma, Autism Spectrum Disorder, Bipolar Disorder, Cancer, Colitis/Crohn’s, Depression, Diabetes, Endocrine Disorders, Epilepsy/Seizure, Fibromyalgia, Glaucoma, Heart Disease, Huntington’s Disease, Inflammatory Disorders, Irritable Bowel Syndrome, Kidney Disease, Liver Disease, Metabolic Syndrome, Migraines, Mood Disorders, Motion Sickness, Multiple Sclerosis, Nausea, Neurodegeneration, Neuropathic Pain, Obesity, OCD, Osteoporosis, Parkinson’s Disease, Prion/Mad Cow Disease, PTSD, Rheumatism, Schizophrenia, Sickle Cell Anemia, Skin Conditions, Sleep Disorders, Spinal Cord Injury, and Stress Stroke/TBI.

cannabinoid-education

Raluca Schachter: What should we look for in terms of quality when we choose cannabis oil?

Steven Sinay: Since cannabis oil products have only been in the market place for a short period of time, it is important to source these products just as you would your produce, meat, fish, etc. As far as I can tell there are not a lot of regulatory organizations monitoring the quality and purity of these sources. Be sure to look for a product that has gone through some sort of third party lab testing that detect contaminants like pesticides, fungicides, mycotoxins, microbes, etc. Equally as important consumers need to be aware of the concentration of their medicinal cannabis.  It is fundamental in allowing the consumer to choose the correct medicine for their symptoms, as well as determining the proper dose. It’s good practice to find a manufacturer that is not afraid to allow access to each Certificate of Analysis on every batch they produce.

Raluca Schachter: In what countries can cannabis oil be bought, legally speaking?

Steven Sinay: As long as the CBD oil product is purchased from a non THC Hemp oil source it should be legal in all countries. Here in the United States a non THC CBD product is classified as a dietary supplement and is legal in all 50 states.

Raluca Schachter: The nutritional world is quite flooded with hypes these days. But as we know through Metabolic Typing, there is no nutrient, remedy or food that can be beneficial for everybody. Any nutrient has different effects in different metabolisms, biochemically speaking. So there are no one size fits all remedies, really. From your experience, have you had the chance to observe how this remedy had different effects in different metabolisms?

Steven Sinay: As previously mentioned, at the right dosage, CBD has been shown to significantly help with anxiety, pain, neurodegeneration, inflammation, etc. An appropriately high dosage of CBD will give you all the desired effects you need, and there is really no risk of overdose as CBD is harmless even in high concentrations. However, most people will feel little effect if they take too low a dosage, effectively wasting CBD’s powerful beneficial properties.

With the above in mind, the importance of correct CBD dosage becomes obvious. People with different requirements and different metabolisms will need accordingly different CBD dosages to experience CBD’s positive effects, and dosages can vary dramatically because there is no one-size-fits-all “typical CBD dosage.” While there is no such thing as “too much CBD,” you can in fact take too little to feel a difference. Dosage can range anywhere from 2-3 mg, up to 100 mg, 200 mg,  or 500 mg to 1000 mg on the super high end. Remember, you cannot overdose and there are no reported side effects from taking high concentrations of CBD. Most people only need around 2-3 mg per day to start feeling a difference. Yet people with stronger needs may need to start at a lower dose and work their way up until they find the right dose for their body.

Raluca Schachter: What are your thoughts regarding the future of cannabis in the medical field?

Steven Sinay:  This is the $64,000 Dollar Question! With our government holding a patent on several Cannabinoids, it leads one to be a little skeptical. Why? The forces that would keep cannabis illegal are vocal and very well-funded, but they are not impervious to persistent effort. The lynch pin in the War on Drugs has always been cannabis. Without the suppression and interdiction of this popular and widely used substance, there simply would not be enough “illegal drug use” going on to justify the huge amount of money and resources spent on “fighting drugs.” Once again all based on the all mighty dollar!

I feel CBD and other Cannabinoids with the persistence from those who can, and are truly benefiting from its medicinal properties, along with natural healers promoting its use, will find its place in future modern medicine. Time will tell.

Novel oral prophylaxis tames hereditary angioedema


VITALS

Key clinical point: A safe and effective oral daily drug for reducing the frequency of hereditary angioedema attacks is in the works.

Major finding: The mean angioedema attack rate was 1.27 episodes per week while patients were on placebo and significantly less at 0.82 attacks per week while they were on BCX4161.

Data source: OPuS-1, a randomized, double-blind, placebo-controlled crossover study, including 24 patients with severe hereditary angioedema.

 A targeted oral medication for the prevention of potentially life-threatening episodes of hereditary angioedema produced a clinically meaningful reduction in attack frequency in a double-blind, placebo-controlled phase II study.

“This is very exciting. Without exaggeration, this is one of the deadliest and most challenging diseases that we deal with as dermatologists. What these patients want is oral prophylaxis, and we’ve got proof of concept with this trial. This is a bright new future for patients with hereditary angioedema, ” Dr. Marcus Maurer said in presenting the results of the OPuS-1 (Oral Prophylaxis for Hereditary Angioedema) trial at the annual congress of the European Academy of Dermatology and Venereology.

Dr. Marcus Maurer
Dr. Marcus Maurer 

The investigational agent BCX4161 is a potent oral inhibitor of plasma kallikrein, which plays a key role in hereditary angioedema (HAE) by inducing vasodilation, edema, and nonvascular smooth muscle contraction.

OPuS-1 was a double-blind, randomized crossover study in which 24 patients with severe HAE were assigned to 4 weeks of BCX4161 at 400 mg or placebo three times daily, then switched to 4 weeks of the other regimen after a washout period. Participants averaged 42 years of age with a mean 32-year duration of HAE. At enrollment, they averaged 1.5 attacks per week, and they had a mean of 1.2 emergency department visits for HAE during the previous year. Twenty of the 24 patients had a history of one or more laryngeal attacks, the most serious manifestation of HAE, which eventually results in death by strangulation in roughly 30% of affected individuals, explained Dr. Maurer, professor of dermatology and allergy at Charité University Hospital in Berlin.

The primary outcome was the adjudicated attack rate, which was 1.27 attacks per week with placebo and a significantly lower 0.82 per week while patients were on BCX4161. Attacks averaged 20-23 hours in duration. Three patients were attack free on BCX4161; none was attack free during the placebo phase.

The novel agent also resulted in significant improvement on the secondary endpoints of quality of life and disease activity. Quality of life, as measured by the Angioedema Quality of Life questionnaire, improved by 8.4 points from baseline during active treatment, compared with 0.5 points with placebo. Disease activity, as assessed by the Angioedema Activity Score, or AA28, decreased while patients were on BCX4161, with a mean score of 21.4 vs. 28.8 with placebo.

The tolerability and side effects of BCX4161 were the same as with placebo. The rate of treatment compliance was 98%.

HAE is a rare and debilitating genetic disease with an estimated prevalence of 1 in 50,000. The most common symptoms include asymmetric swelling of the hands, feet, face, genitals, airway, and GI tract. HAE is caused by a deficiency of the C1 inhibitor, with resultant accumulation of bradykinin. By inhibiting plasma kallikrein, BCX4161 curbs bradykinin production.

“This disease has nothing to do with histamine or mast cells. This is not allergy or urticaria,” Dr. Maurer noted.

Re-fuel Every 100 Years With the New Thorium Car



watch the video.URL:

If you haven’t yet been amazed by the hybrid car that runs on air or the water-powered engine, this vehicle is sure to make you think twice about the alternative forms of transportation which will one day rule the road.

The new Thorium car, created by a company called Laser Power Systems, is completely emission-free, turbine-free, and is electricity generated. It’s one of the new sustainable-powered engines to show just how unnecessary modern day propulsion engines are and also offer an exciting alternative.

Fueled by nuclear thorium lasers, this engine only needs 8 grams of fuels every 100 years. Charles Stevens, the CEO and chairman of the Connecticut-based company, claims that one gram of thorium yields the energy of 7,500 gallons of gasoline.  Harnessed by heating the energy from an external source, the energy becomes so dense the molecules produce heat. A vehicle that needs refilling once a lifetime.

It seems many countries and military agencies have been experimenting with this type of energy to power vehicles for a number of years. And now with designs to create a car for the public, those who find their gasoline budget a sensitive topic may find relief in this model.

Go Thorium sheds insight to its long-time study: “What China is attempting is to turn the nuclear clock back to the mid-1960s, when Oak Ridge successfully operated a reactor with fuel derived from thorium and cooled with molten salts. The lab also produced detailed plans for a commercial-scale power plant. Despite considerable promise, the thorium test reactor was shut down in 1969 after about five years of operation. Research was effectively shelved when the Nixon Adminsitration decided in the 1970’s that the U.S. Nuclear industry would concentrate on a new generation of uranium-fueled, fast-breeder reactors. For a range of technical and political reasons, not least the public’s fear of nuclear plants, these new uranium reactors have yet to come into widespread commercial use.”

Thorium is a naturally occurring radioactive element, and may be best known for its potential to replace current nuclear energy generation by implementing reactors fueled by thorium. This element is an alternative for the use of uranium, therefore it’s a much safer fuel for civilian power plants.

Fang Jinqing, a retired nuclear researcher at the China Institute of Atomic Energy shared his thoughts on the subject, “If a thorium, molten-salt reactor can be successfully developed, it will remove all fears about nuclear energy.” In addition, “The technology works in theory, and it may have the potential to reshape the nuclear power landscape, but there are a lot of technical challenges.”

It is quite clear that modern day nuclear reactors are no longer needed. The technologies to fuel alternative modes of transportation are becoming more widely implemented, and with growing awareness surrounding the necessity to adopt greener transportation, no doubt their prevalence in mainstream society will grow in time.

Read More: http://www.trueactivist.com/re-fuel-every-100-years-with-the-new-thorium-car/

If you haven’t yet been amazed by the hybrid car that runs on air or the water-powered engine, this vehicle is sure to make you think twice about the alternative forms of transportation which will one day rule the road.

The new Thorium car, created by a company called Laser Power Systems, is completely emission-free, turbine-free, and is electricity generated. It’s one of the new sustainable-powered engines to show just how unnecessary modern day propulsion engines are and also offer an exciting alternative.

Fueled by nuclear thorium lasers, this engine only needs 8 grams of fuels every 100 years. Charles Stevens, the CEO and chairman of the Connecticut-based company, claims that one gram of thorium yields the energy of 7,500 gallons of gasoline.  Harnessed by heating the energy from an external source, the energy becomes so dense the molecules produce heat. A vehicle that needs refilling once a lifetime.

It seems many countries and military agencies have been experimenting with this type of energy to power vehicles for a number of years. And now with designs to create a car for the public, those who find their gasoline budget a sensitive topic may find relief in this model.

Go Thorium sheds insight to its long-time study: “What China is attempting is to turn the nuclear clock back to the mid-1960s, when Oak Ridge successfully operated a reactor with fuel derived from thorium and cooled with molten salts. The lab also produced detailed plans for a commercial-scale power plant. Despite considerable promise, the thorium test reactor was shut down in 1969 after about five years of operation. Research was effectively shelved when the Nixon Adminsitration decided in the 1970’s that the U.S. Nuclear industry would concentrate on a new generation of uranium-fueled, fast-breeder reactors. For a range of technical and political reasons, not least the public’s fear of nuclear plants, these new uranium reactors have yet to come into widespread commercial use.”

Thorium is a naturally occurring radioactive element, and may be best known for its potential to replace current nuclear energy generation by implementing reactors fueled by thorium. This element is an alternative for the use of uranium, therefore it’s a much safer fuel for civilian power plants.

Fang Jinqing, a retired nuclear researcher at the China Institute of Atomic Energy shared his thoughts on the subject, “If a thorium, molten-salt reactor can be successfully developed, it will remove all fears about nuclear energy.” In addition, “The technology works in theory, and it may have the potential to reshape the nuclear power landscape, but there are a lot of technical challenges.”

It is quite clear that modern day nuclear reactors are no longer needed. The technologies to fuel alternative modes of transportation are becoming more widely implemented, and with growing awareness surrounding the necessity to adopt greener transportation, no doubt their prevalence in mainstream society will grow in time.

 

HIV Immunity: Genetic Variation And Antiviral Enzymes Explain Why Some People Are Naturally Immune To HIV


shutterstock_62057377
Some people have a particular variation of APOBEC3H, a gene which produces an antiretroviral protein that protects cells by inhibiting the replication of HIV. 

“We have seven APOBEC3 genes within the variants of human population,” Dr. Reuben S. Harris, a professor in the department of Biochemistry, Molecular Biology and Biophysics, explained to Medical Daily. Of these seven genes, “only APOBEC3H varies within the human population,” Harris added. APOBEC3H itself has seven variations, and if you broadly group these into those that make stable and those that make unstable proteins, Harris told Medical Daily, “What we found is those that are stable confer resistance to some forms of HIV.”

This important finding may pave the way to new treatments and drugs.

Viral Infectivity Factor

Viruses are often described as the ultimate parasite. They cannot reproduce or sustain themselves on their own, so they require a host. In the case of the human immunodeficiency virus, their host-of-choice is T lymphocyte cells found in the immune system. After gaining control of the molecular machinery of T-cells, the virus duplicates itself and then destroys its host. Naturally, this damages the immune system and so people infected with HIV become increasingly susceptible to any pathogen deciding to invade their bodies, including diseases like cancer.

However, this picture is somewhat simplistic. T lymphocytes possess their own defense mechanism in the form of antiretroviral proteins produced by the APOBEC3 genes. In turn, HIV has its own counter-defense — a protein referred to as viral infectivity factor (Vif), which tricks T lymphocytes into destroying APOBEC3 enzymes.

For the current study, then, a group of researchers led by Harris and doctoral student Eric Refsland decided to examine this interaction closely. They hypothesized that different levels of susceptibility to HIV-1 might be related to variations in the gene producing this antiretroviral protein.

Testing their theory, Harris and his colleagues first discovered that an HIV-1 infection increased APOBEC3H proteins. This, then, had to be an important part of the HIV susceptibility equation. Next, they “essentially took HIV strains,” Harris told Medical Daily,“And we figured out what amino acids are required to counteract APOBEC3H.” This was done by creating mutant probes to test how important a stable protein compared to an unstable protein might be when fighting off an HIV infection. “This is key,” Harris told Medical Daily. “If you can’t generate these mutants, it’s difficult to interpret the cell data.”

After creating the necessary probes, then, the research team used cells from donors and found different people with different genetic variations of APOBEC3H produced stronger and more stable antiretroviral proteins. The stable variations, the researchers found, successfully blocked HIV-1’s ability to replicate itself in cases where the strain of HIV had a weak version of Vif.

Unfortunately, when the HIV-1 virus had a strong version of Vif, the protective proteins no matter how stable or potent lost their battle to infection.

Going forward, Harris says, he and his colleagues hope to learn ways to stop Vif from harming the APOBEC3 enzymes. “One could imagine drugs that stop Vif from binding with APOBEC,” Harris said in a press release. Believing this to be “a bonafide HIV killing pathway,” Harris and his co-researchers want to activate it in infected persons. This approach might indefinitely suppress the virus and stop it from replicating, he speculates, or it could even result in curing HIV.

Source: Refsland EW, Hultquist JF, Luengas EM, et al. Natural Polymorphisms in Human APOBEC3H and HIV-1 Vif Combine to Affect Viral Infectivity and G-to-A Mutation Levels in Primary T Lymphocytes. PLOS Genetics. 2014.

Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases


Importance  Because vaccinations are common, even a small increased risk of multiple sclerosis (MS) or other acquired central nervous system demyelinating syndromes (CNS ADS) could have a significant effect on public health.

Objective  To determine whether vaccines, particularly those for hepatitis B (HepB) and human papillomavirus (HPV), increase the risk of MS or other CNS ADS.

Design, Setting, and Participants  A nested case-control study was conducted using data obtained from the complete electronic health records of Kaiser Permanente Southern California (KPSC) members. Cases were identified through the KPSC CNS ADS cohort between 2008 and 2011, which included extensive review of medical records by an MS specialist. Five controls per case were matched on age, sex, and zip code.

Exposures  Vaccination of any type (particularly HepB and HPV) identified through the electronic vaccination records system.

Main Outcomes and Measures  All forms of CNS ADS were analyzed using conditional logistic regression adjusted for race/ethnicity, health care utilization, comorbid diseases, and infectious illnesses before symptom onset.

Results  We identified 780 incident cases of CNS ADS and 3885 controls; 92 cases and 459 controls were females aged 9 to 26 years, which is the indicated age range for HPV vaccination. There were no associations between HepB vaccination (odds ratio [OR], 1.12; 95% CI, 0.72-1.73), HPV vaccination (OR, 1.05; 95% CI, 0.62-1.78), or any vaccination (OR, 1.03; 95% CI, 0.86-1.22) and the risk of CNS ADS up to 3 years later. Vaccination of any type was associated with an increased risk of CNS ADS onset within the first 30 days after vaccination only in younger (<50 years) individuals (OR, 2.32; 95% CI, 1.18-4.57).

Conclusions and Relevance  We found no longer-term association of vaccines with MS or any other CNS ADS, which argues against a causal association. The short-term increase in risk suggests that vaccines may accelerate the transition from subclinical to overt autoimmunity in patients with existing disease. Our findings support clinical anecdotes of CNS ADS symptom onset shortly after vaccination but do not suggest a need for a change in vaccine policy.

%d bloggers like this: